Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Regeneron Expands CytomX Partnership to $4 Billion in Potential Milestones for Conditionally-Activated Bispecific Cancer Therapies

Fineline Cube Jun 4, 2026
Company Deals

Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases

Fineline Cube Jun 4, 2026
Company Deals

Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market – First Global Copycat of Trulicity

Fineline Cube Jun 4, 2026
Company Deals

Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China

Fineline Cube Jun 3, 2026
Company Deals

Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market

Fineline Cube Jun 3, 2026
Policy / Regulatory

FDA Issues Draft Guidance to Accelerate Gene Therapy Development Through Platform Knowledge Sharing

Fineline Cube Jun 4, 2026
Company Drug

Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia – First Chinese TCM Company to Advance Novel Therapy in US Oncology Market

Fineline Cube Jun 4, 2026
Company Drug

Changchun High & New Tech Secures NMPA Clinical Trial Approval for GenSci155 in Dual Indications: Bronchopulmonary Dysplasia and Acute Ischemic Stroke

Fineline Cube Jun 4, 2026
Company Drug

Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders

Fineline Cube Apr 15, 2026

Shanghai Fosun Pharmaceutical Group Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received regulatory...

Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Fineline Cube Apr 15, 2026

The State Council released the “Opinions on Improving the Drug Pricing Mechanism” this week, introducing...

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes

Fineline Cube Apr 15, 2026

Gan & Lee Pharmaceuticals (SHA: 603087) announced the first subject dosing in a Phase III...

Company Deals

AC Immune and Eli Lilly Amend 2018 Alzheimer’s Partnership to Advance Tau Morphomer Candidates

Fineline Cube Apr 15, 2026

AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE: LLY) announced a revised...

Company Deals

Autobio Diagnostics Expands Global IVD Footprint with Dual Vietnam Partnerships

Fineline Cube Apr 15, 2026

Autobio Diagnostics Co., Ltd. (SHA: 603658) announced this week it has executed separate strategic partnership...

Company Deals

Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma

Fineline Cube Apr 15, 2026

Er-Kim announced on April 14, 2026, that it has signed an exclusive commercialization agreement with...

Company Deals

UCB Secures EU Approval for Kygevvi as First-Ever Treatment for Ultra-Rare TK2 Deficiency

Fineline Cube Apr 15, 2026

UCB (EBR: UCB) announced that the European Commission (EC) has granted marketing approval under exceptional...

Company

Eli Lilly Restructures China Cardiometabolic Division Ahead of Foundayo Oral GLP-1 Launch

Fineline Cube Apr 15, 2026

Eli Lilly and Company’s (NYSE: LLY) China unit announced a comprehensive organizational restructuring and key...

Company Drug

Huadong Medicine’s Semaglutide Biosimilar HDM1702 Enters NMPA Review for Weight Management Indication

Fineline Cube Apr 15, 2026

Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has...

Company Deals

Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal

Fineline Cube Apr 15, 2026

Lepu Medical Technology (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, announced it...

Company Deals

Eli Lilly to Acquire CrossBridge Bio for Up to $300 Million to Bolster ADC Pipeline with Novel TROP2-Targeting Candidate

Fineline Cube Apr 15, 2026

Eli Lilly and Company (NYSE: LLY) announced plans to acquire CrossBridge Bio, a Houston-based biotechnology...

Company Drug

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Fineline Cube Apr 15, 2026

Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced positive top-line results from a Phase III...

Company

Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance

Fineline Cube Apr 15, 2026

Johnson & Johnson (J&J, NYSE: JNJ) reported first-quarter 2026 results on April 14, 2026, showcasing...

Company Drug

Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori

Fineline Cube Apr 15, 2026

Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National...

Company Drug

Shanghai Henlius Biotech Launches Phase I Trial for HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Fineline Cube Apr 15, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696), a leading Chinese biopharmaceutical company, announced it has received...

Company Medical Device

Beijing Sinotau’s Prostate Cancer Diagnostic Agent XTR020 Receives NMPA Review Acceptance

Fineline Cube Apr 15, 2026

Beijing Sinotau International Pharmaceutical Technology Co., Ltd., a specialized nuclear medicine enterprise, announced that the...

Policy / Regulatory

FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing

Fineline Cube Apr 15, 2026

The U.S. Food and Drug Administration (FDA) released draft guidance on Monday outlining standardized methods...

Company Deals

WinHealth Pharma Licenses World’s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment

Fineline Cube Apr 14, 2026

Hong Kong WinHealth Pharma Group has entered a licensing agreement with fellow Hong Kong firm...

Company Medical Device

Roche’s Elecsys NfL Test Gains CE Mark for Blood-Based Multiple Sclerosis Neuroinflammation Monitoring

Fineline Cube Apr 14, 2026

Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced on 13 April 2026 that its Elecsys Neurofilament...

Company Deals

Thermo Fisher’s PPD Secures 270M-Patient HealthVerity Dataset for AI-Driven Clinical Trial Optimization

Fineline Cube Apr 14, 2026

Thermo Fisher Scientific (NYSE: TMO) announced a strategic data collaboration with HealthVerity, the leading real-world...

Posts pagination

1 … 26 27 28 … 677

Recent updates

  • Regeneron Expands CytomX Partnership to $4 Billion in Potential Milestones for Conditionally-Activated Bispecific Cancer Therapies
  • Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases
  • Medtronic Submits FDA 510(k) Filings to Expand Hugo RAS System into General and Gynecologic Surgery, Adds LigaSure Maryland Instrument
  • Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia – First Chinese TCM Company to Advance Novel Therapy in US Oncology Market
  • Changchun High & New Tech Secures NMPA Clinical Trial Approval for GenSci155 in Dual Indications: Bronchopulmonary Dysplasia and Acute Ischemic Stroke
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Regeneron Expands CytomX Partnership to $4 Billion in Potential Milestones for Conditionally-Activated Bispecific Cancer Therapies

Company Deals

Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases

Company Medical Device

Medtronic Submits FDA 510(k) Filings to Expand Hugo RAS System into General and Gynecologic Surgery, Adds LigaSure Maryland Instrument

Company Drug

Yunnan Baiyao Secures FDA Clinical Approval for INB301 in Tumor Cachexia – First Chinese TCM Company to Advance Novel Therapy in US Oncology Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.